Fosun pharma backed, BioNTech hires Jens Holstein as CFO

Jens Holstein will oversee a massive inflow of cash that will potentially fuel the ambitions of BioNTech's co-founder and Chief Executive Ugur Sahin to develop precision immunotherapies against various forms of cancer and other diseases.

Previously, Holstein served in various finance and management positions at diversified healthcare group Fresenius SE.

BioNTech, the Pfizer partner that invented the Comirnaty COVID-19 vaccine, has appointed former Morphosys executive Jens Holstein as the chief financial officer to help it grow into a global immunotherapy company. Vaccine supply deals lined up for this year alone are worth 12.4 billion euros ($15.1 billion) in revenue for BioNTech, with more contracts on the cards.

As per the source, Fosun Pharma unit, BioNTech to form joint venture to make up to 1 billion doses of Covid-19 vaccine in China. The Fosun unit will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how.

Fosun Pharmaceutical Industry shall provide a manufacturing facility, which has the potential capacity of producing up to one billion doses of coronavirus vaccine product per annum, and shall inject the manufacturing facility into the joint venture,” Fosun Pharmaceutical said in a statement.